DRL To Present New Find At AHASSs

Hyderabad, Nov 7: | Updated: Nov 8 2003, 05:30am hrs
For the second consecutive year, an abstract describing preclinical research in Dr Reddys Laboratories Ltd atherosclerosis therapeutics programme has been selected for presentation at the annual American Heart Association Scientific Sessions (AHASSs). The annual session is scheduled for November 9 in Orlando, Florida.

...Launches S African Arm
Our Corporate Bureau

Hyderabad, Nov 7: In a bid to offer a range of high-quality pharmaceutical products to the South African medical fraternity, Dr Reddys Laboratories has launched a South African subsidiary, Dr Reddys Laboratories Private Ltd, South Africa (Dr Reddys SA).
The subsidiary has been started with Venturepharm Private Ltd, a member of the J&J group of companies.
While Dr Reddys holds 60 per cent, Venturepharm holds 40 per cent share in the subsidiary, a company press release said.
The compnay aims to use South Africa as the gateway towards penetrating and establishing a presence in SADEC regions and Sub-Saharan African territories and at the same time developing a significant presence in the South African markets.
Dr Reddys SA will act as an applicant for local registration purposes and will be responsible for distribution, marketing, sales and business development of Dr Reddys pipeline and other selected licensed products, added the release.

Last year also, the company had presented research findings on cardiovascular related disease from its research centre in Atlanta.

It may be mentioned that American Heart Association Scientific Sessions are the premier meetings for presentation of new scientific information on cardiovascular disease and novel therapeutic approached to cardiovascular disease. The presentation by Dr Reddys will describe scientific findings in a new approach to the treatment of Atherosclerosis.

Atherosclerosis is a disease in which blood transporting arteties are clogged and cause major cardiovascular complications such as heart attacks and stroke. The current treatment strategies for the disease are indirect and partially effective, according to a press release.